Kornimate/medical-research-clean huggingface dataset:
qt-logs : artificial intelligence for qt interval analysis of ecg from smartwatches in patient receiving treatment for covid-19

Conditions: COVID-19

Summary: this observational pilot prospective study will evaluate a new method for remote monitoring of corrected qt measurement using an artificial intelligence (ai)-based solution and ecg data collected via smartwatches (ai-qtc), in patients ambulatory treated with the hc-az combination, at the early stage of covid-19 infection, at a tertiary hospital center. daily ecgs will be performed via the smartwatches. ai-qtc will be compared to standard manual qtc reviewed by cardiologist. correlation and agreement between measures will be assessed.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * sars-cov-2 confirmed infection by positive nasopharyngual pcr * prescription of association hydroxychloroquine and azythromycine for covi-19 therapy * patient's smartphone able to download the smartwatches application exclusion criteria: * presence of a pacemaker * pregnant or breastfeeding females * refusal to participate * incapacity * adult under legal protection (trusteeship, guardianship)
the effectiveness and safety of apixaban in nvaf patients with history of osteoporosis and/or fracture: a nation-wide population based study

Conditions: Atrial Fibrillation

Summary: old age, less body weight and deteriorated renal function are significant clinical factors for the outcomes of atrial fibrillation- so called 'fragile'- and these are common risk factors in osteoporosis and fracture. therefore, in real world, these risk factors and co-morbidities are commonly considered when it comes to prescribe anticoagulant in atrial fibrillation patients. recent study even reported that comorbid atrial fibrillation in patients with osteoporosis might be associated with an increased risk of bone fracture and death after fracture. because there have been very few data about the effectiveness/safety of anticoagulant among non-valvular atrial fibrillation with prior osteoporosis/fracture, this study is planned to provide real-world evidences for this specific type of non-valvular atrial fibrillation patients.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older on the index date * patients had ≥1 medical claim for atrial fibrillation with at least one hospitalization or at least two outpatient visits during the reference period exclusion criteria: * patients with valvular atrial fibrillation or transient atrial fibrillation * having ≥ 2 types of oral anticoagulant on the index date * who have contraindications to oral anticoagulant * confounder factors related to the outcome (osteoporotic fractures)
effect of slc01b1 (rs2306283) polymorphism on the efficacy and safety profile of atorvastatin in pakistani population

Conditions: Hyperlipidemias

Summary: the goal of this prospective cohort study was to identify the effect of slc01b1 gene polymorphism in the pakistani population. the main questions it aims to answer are: to identify polymorphism in sloc1b1 (rs2306283) in the pakistani population. to determine the association between sloc1b1 (rs2306283) polymorphism and the clinical efficacy of atorvastatin to determine the association between sloc1b1 (rs2306283) polymorphism and the safety profile of atorvastatin.

the goal of this prospective cohort study was to identify the effect of slc01b1 gene polymorphism in the pakistani population, due to the high prevalence of this variant in the pakistani population the main questions it aims to answer are: to identify polymorphism in sloc1b1 (rs2306283) in the pakistani population. to determine the association between sloc1b1 (rs2306283) polymorphism and the clinical efficacy of atorvastatin to determine the association between sloc1b1 (rs2306283) polymorphism and the safety profile of atorvastatin. the participants' blood samples were taken and further genotyping was performed using conventional tetraarms pcr. the results were visualized by gel electrophoresis.

Eligibility criteria:
inclusion criteria: 1. pakistani individuals aged between 30 to 60 years 2. patients with deranged lipid profile 3. newly diagnosed patients of dyslipidemia taking atorvastatin (lipiget) 10mg/day 4. normal hepatic and renal function exclusion criteria: 1. patient taking other lipid-lowering medications 2. moderate and severe systemic diseases 3. pregnancy 4. patients taking medications and diet that can interact with atorvastatin 5. hypothyroidism 6. recent history of surgical procedure or trauma
return to work with post stroke communication disorders

Conditions: Stroke

Summary: approximately a quarter of stroke survivors are of working age, and it is well-known that disabilities caused by stroke can lead to difficulties returning to work. in addition to the economic cost, being out of the workplace due to disability has major psychosocial costs for the individual, causing reduced sense of purpose, quality of life, and standard of living. communication problems (which can affect reading and writing, as well as producing and understanding speech) are not as visible as other stroke-related problems such as a weak arm or difficulties walking. however, they can cause major problems for returning to work because of the importance of communication across a vast range of work activities, for example as a means to engage with colleagues, to share information in order to solve problems and resolve conflicts, and as a means to ensure health and safety. there has been little research into the effects of communication problems on returning to work after a stroke, so the investigators want to explore this issue. specifically, the investigators want to find out what helps and what hinders people with communication disorders following a stroke when they attempt to return to work; what information and support is most helpful to them; how this information and support should be given and by whom. the investigators aim to do this by interviewing people across nhs grampian who have the experience of attempting to return to work with post-stroke communication problems. the investigators will then look at all the interviews together and find the common feelings or experiences that the participants mentioned. the findings will be written up and shared widely with professionals and with stroke survivors. the knowledge gained will help the investigators to plan a programme to help people with these problems to return to work.


Eligibility criteria:
inclusion criteria: adults (aged 18 years of age and over) will be eligible if: * they have had a stroke (excluding transient ischemic attacks, or mini strokes) within the last 2 years * they were in paid employment or actively seeking work at the time of their stroke * they are attempting or have attempted (whether or not successfully) to return to paid employment since their stroke. exclusion criteria: individuals will be excluded if: * they lack the capacity to consent * they are considered to have insufficient english language skills to be able to engage effectively in an interview, given that this is a small-scale study which will not have the resources to fund interpreter services * they have a diagnosis of a learning disability, dementia or another comorbidity deemed to be as or more significant than the stroke in their experience of return to work.
long term follow up of sub-retinal transplantation of hesc derived rpe cells in patients with amd

Conditions: Age-Related Macular Degeneration

Summary: the purpose of his study is to evaluate the long term safety and tolerability of ma09-hrpe cellular therapy in patients with advanced dry age-related macular degeneration (amd) from one to five years following the surgical procedure to implant the ma09-hrpe cells.

this study is a long term, follow up to the act ma09-hrpe 001 phase i/ii trial. the phase i/ii trial (referred to as the core protocol) was an open-label, non randomized, dose escalation, multi-center trial. thirteen amd patients were treated in this trial. ten patients with profound vision loss (visual acuity \<= 20/400) received a single subretinal injection of ma09-hrpe cells, starting at a dose of 50,000 ma09-hrpe cells transplanted (three patients), 100,000 ma09-hrpe cells transplanted (three patients), 150,000 ma09-hrpe cells (three patients) and increasing to a maximum dose of 200,000 ma09-hrpe cells transplanted (one patient). three patients with severe to moderate loss (visual acuity \<= 20/100) received a dose of 100,000 ma09-hrpe cells. all patients who participated in the core protocol are eligible for participation in this follow-up protocol. the first visit of this long term follow-up protocol will correspond to the last visit of the core protocol, and will take place at 12 months post cell implantation. informed consent will be obtained at this visit. patients will be evaluated at 18, 24, 36, 48 and 60 months post-transplant (or more frequently as clinically indicated). follow-up will include obtaining information about ophthalmological findings and events of special interest as defined in the primary outcome. at the last visit of this follow-up study, whether at 60 months post-transplant or at early discontinuation, patients will be invited to participate in a safety surveillance study for an additional 10 years under a separate protocol which will continue to monitor the long term risks of ma09-hrpe cell transplantation.

Eligibility criteria:
inclusion criteria: * must have been treated with hesc-rpe cell transplant in the core protocol. * able to understand and willing to sign the informed consent to participate in the follow up study. exclusion criteria: - there are no exclusion criteria.

Keywords: dry amd geographic atrophy asp7316
cacaf2 study: catheter ablation for cure of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the objective of this prospective multicenter randomized study is to establish the effectiveness of treatment of persistent atrial fibrillation by encircling the pulmonary veins with radiofrequency (rf) ablation and creating additional lines of block with the aid of the navistar® thermocool® catheter in conjunction with the carto™ ep navigation system. effectiveness will be determined by comparing the chronic success of ablation therapy versus antiarrhythmic drug therapy, defined as the absence of persistent tachyarrhythmias during the first 24 months after a run-in phase of 2 months.


Eligibility criteria:
inclusion criteria: * 18-70 years * written informed consent * one documented relapse of atrial fibrillation (af) during antiarrhythmic drug therapy after an electrical cardioversion exclusion criteria: * permanent atrial fibrillation * patients who had tried \>1 antiarrhythmic drug (class i or class iii). * af was the sole rhythm for \>6 months before the enrollment. * previous ablation for af. * af is deemed secondary to a transient or correctable abnormality including electrolyte imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy. * patients who have fibrillation episodes triggered by another uniform arrhythmia (eg, atrial flutter or atrial tachycardia). * patients with intra-atrial thrombus, tumor, or another abnormality that precludes catheter introduction. * patients with wolf-parkinson-white syndrome. * patients awaiting cardiac transplantation. * congestive heart failure (chf) new york heart association (nyha) class ii-iii-iv or ejection fraction (ef) \<40%. * patients with unstable angina or acute myocardial infarction within 3 months. * patients with cardiac revascularization or other cardiac surgery within 6 months. * patients with heart disease in which corrective surgery is anticipated. * patients in whom appropriate vascular access is precluded. * pregnant women. * a separate requirement for antiarrhythmic drug treatment, which will require an antiarrhythmic drug not previously tried for af suppression. * prior atrial surgery. * contraindication to treatment with warfarin or other bleeding diathesis. * renal failure requiring dialysis. * hepatic failure. * participant in investigational clinical or device trial. * unwilling or unable to give informed consent. * inaccessible for follow-up. * psychological problem that might limit compliance. * active abuse of alcohol or other drugs which may be causative of af. * an implanted device (pacemaker or cardioverter-defibrillator). * left atrial diameter (anteroposterior) \>50 mm.
comparison between effects of two iron preparations on protein in the urine

Conditions: Kidney Failure, Chronic; Anemia, Iron-Deficiency

Summary: this study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein


Eligibility criteria:
inclusion criteria: * moderate to severe anemia * iron deficiency * moderate to severe chronic kidney disease, not receiving dialysis * age ≥ 18 or greater and able to give informed consent exclusion criteria: * known sensitivity to sodium ferric gluconate complex in sucrose injection, iron sucrose usp, or any of their components * clinically unstable * indication of iron sufficiency * bladder obstruction conditions that would not allow for good urine output
viral clearance and epidemiological characteristics in patients with monkeypox

Conditions: Monkeypox

Summary: the present observational study has been designed to understand the dynamics of viral clearance amongst patients with confirmed monkeypox, by quantifying monkeypox viral load in different specimens trough time, to better inform decision-making about patient management and isolation guidelines. also, an immune analysis will be performed in a subset of individuals to describe humoral and cellular responses to monkeypox.

starting in early may 2022 a large number of cases of monkeypox have been reported in non-endemic countries. although initial cases appeared to be linked to travel, the majority of subsequent cases appear to have no travel associated risk factors and these cases have predominantly occurred amongst men who have sex with men (msm) suggesting autochthonous transmission associated with sexual networks. monkeypox is known to be transmitted by close contact with skin lesions of infected individuals and/or via droplets. it is known that the virus can be detected from skin lesions, in blood, in throat swabs and on occasion urine samples. there is limited information as to whether the virus can be detected or persist in other sites including semen. serial virological monitoring has been conducted in a small number of individuals and demonstrates that prolonged shedding for at least 2-3 weeks appears to be relatively common. to help control the current outbreak health authorities have used a number of strategies including identifying and isolating cases of monkeypox combined with contact tracing and limited use of ring-vaccination strategies. because the number of cases seen outside of endemic areas has previously been limited, there is inadequate data to guide decision-making about the duration of isolation, but this is critical to the management of the current outbreak. the present observational study has been designed to understand the dynamics of viral clearance amongst patients with confirmed monkeypox, by quantifying monkeypox viral load in different specimens trough time, to better inform decision-making about patient management and isolation guidelines. also, an immune analysis will be performed in a subset of individuals to describe humoral and cellular responses to monkeypox.

Eligibility criteria:
* inclusion criteria 1. adult male or female individuals of ≥18 years old. 2. examined by a specialist in sexually transmitted infections (stis) and found to have lesions suggestive of monkeypox. 3. symptomatic with symptoms onset date ≤10 days prior to screening/baseline visit. 4. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the trial. 5. has understood the information provided and capable of giving informed consent. * exclusion criteria: 1. severe disease - defined as requires admission to hospital 2. inability to consent and/or comply with trial protocol 3. an alternative confirmed diagnosis that can fully explain the illness

Keywords: monkeypox viral clearance viral dynamics
airway secretion clearance in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to compare the effect of three airway secretion clearance techniques (chest physical therapy, flutter device and high frequency chest wall oscillation) on decline in pulmonary function over a three year period in patients with cystic fibrosis.

study design: randomized clinical trial with pulmonary function testing obtained every three months in each of the three treatment groups. change in slope of fev1 will be compared. days of hospitalization and use of oral or iv antibiotics for respiratory tract infection, quality of life, subject satisfaction, and compliance will also be compared. sample size: enrollment will be completed after 180 subjects have been recruited. fifteen cf centers will participate. subject selection: subjects must have the diagnosis of cf, be \> 7 years of age and have an fev1 \> 45% of predicted. prescribed therapy: each subject will receive airway secretion clearance twice a day. outcomes: change in slope of fev1; days of hospitalization and use of oral or iv antibiotics for respiratory tract infection; quality of life; subject satisfaction; compliance.

Eligibility criteria:
inclusion criteria: * a proven diagnosis of cf as evidenced by a positive sweat test (as documented by a sweat chloride \>60 meq/l by quantitative pilocarpine iontophoresis), or by the presence of two known cf mutations. * aged 7 or older. * fev1 \>45% (knudson). * able to perform reproducible maneuvers for spirometry at screening as defined by the american thoracic society (ats) and european respiratory society (ers) guidelines. * willing to participate in and comply with the study procedures, and willingness of a parent or legally authorized representative to provide written informed consent. exclusion criteria: * hospitalization for complications of cf, or a respiratory exacerbation resulting in - treatment with iv antibiotics within 60 days prior to screening. * use of any investigational drug or device within 60 days prior to screening. * an episode of gross hemoptysis (\>249 ml) within 60 days prior to screening, or during the course of the study. * a pneumothorax in the six months preceding the study or during the course of the study. * patients who are pregnant or become pregnant. * patients colonized with burkholderia cepacia.

Keywords: cystic fibrosis chest wall oscillation drainage, postural medication adherence patient dropouts
robot-based wrist rehabilitation in orthopaedics: efficacy and comparison with traditional methods

Conditions: Wrist Injuries

Summary: the present randomized clinical trial addresses the issue about the application of robot-based rehabilitation programs in orthopedic conditions. the aim of the study is to test the efficacy of a robot-based rehabilitative protocol to recover wrist functionality after traumatic injuries.

thirty patients with work related wrist injuries resulting in wrist joint dysfunction are enrolled in an open randomized controlled trial over a 24 months period. each participant is randomly allocated to experimental or control group and receives a 3-week rehabilitation program including both assessment and rehabilitative sessions. while patients in the control group undergo a traditional rehabilitative protocol, the experimental group is treated replacing traditional exercises with robot-aided ones performed with wristbot, a 3 degrees of freedom (dofs) robotic exoskeleton. wristbot allows for passive, active and assisted range-of-motion (rom) exercises, isotonic and elastic tasks, proprioceptive and perturbation training. all subjects perform the same sessions of assessment, which include two evaluations through the robotic system and clinical measures at the beginning (tb) and at the end (te) of the rehabilitative training, and a follow-up through phone call, three months after the end of the treatment (tf). the assessment sessions include a robot-based evaluation (measurement of rom, exerted forces, dexterity, and wrist position sense acuity) and clinical measures (patient rated wrist evaluation, jebsen-taylor and jamar test). subjects' level of satisfaction about treatment is asked at the end of the rehabilitative treatment (te). the primary objective is to evaluate the results of a robot-based rehabilitative approach on wrist functionality after work-related trauma, comparing the effects of robotic therapy with those achieved through a conventional therapy.

Eligibility criteria:
inclusion criteria: * functional and spatial limitations of the wrist joint, following an injury occurred at workplace * post-immobilization phase * temporal distance from the acute event not exceeding 6 months * signed informed consent acquisition exclusion criteria: * non-compliance with study requirements * pregnancy or breast feeding; current or prior history of malignancy * open skin at the level of the patient-device interface * sensory deficit at the level of the patient-device interface * acute inflammatory arthritis of the wrist * contraindications to passive movements

Keywords: adult humans middle aged robotics / instrumentation* wrist injuries / physiopathology wrist injuries / rehabilitation*
abdominal ct combined with ai for early screening of liver cancer

Conditions: Hepatocellular Carcinoma

Summary: this study plans to utilize multiphase contrast-enhanced and non-contrast ct（computed tomography） images from 10000 pathologically confirmed liver tumor patients at our hospital. an ai（artificial intelligence） model will be used to outline the 3d contours of liver masses, which will then be refined by radiologists and hepatobiliary-pancreatic surgeons to enhance model accuracy. by incorporating more imaging data, the model's recognition capabilities will be improved, laying the groundwork for prospective clinical trials and aiming to establish a superior ai model for early liver cancer screening based on ct imaging.

this research project intends to utilize multiphase contrast-enhanced and non-contrast ct images from 10000 patients with a full spectrum of liver tumors (such as hcc（hepatocellular carcinoma）, icc（intrahepatic cholangiocarcinoma ）, meta（metastasis）, etc.), confirmed by the pathological gold standard at our hospital. through a pre-established ai model, the 3d contours of various liver masses will be delineated. in collaboration with senior physicians from our hospital's radiology department and hepatobiliary pancreatic surgery department, the ai-drawn contours will be refined to obtain more accurate 3d mass models, thereby enhancing the validation efficacy of the model. by incorporating more radiological data, the precision of the model will be improved, boosting its recognition capabilities and laying a solid foundation for subsequent prospective clinical trials. the ultimate goal is to establish a superior ai model for early screening of liver cancer based on ctimaging.

Eligibility criteria:
inclusion criteria: * from 2019 to 2030, our hospital has collected non-contrast and contrast-enhanced ct images from patients with a full spectrum of liver tumors (such as hcc, icc, meta, etc.), all confirmed by the pathological gold standard exclusion criteria: * patients who have undergone upper abdominal surgery. examples include post-ercp (endoscopic retrograde cholangiopancreatography) for the pancreas, post-external drainage surgery, esophageal surgery, and gastrectomy, among others. * patients who have received systemic treatments such as chemotherapy or traditional chinese medicine. examples include chemotherapy for lymphoma, chemotherapy for leukemia, chemotherapy for lung cancer, and comprehensive treatment for liver cancer, etc. * patients with poor-quality ct images. examples include convolution artifacts caused by the inability to place hands on the sides of the body and respiratory artifacts due to poor breath-holding, etc.

Keywords: artificial intelligence hepatocellular carcinoma lidar